Sanofi
Sanofi is a French multinational pharmaceutical company and one of the world's five largest by revenue, with a global clinical development operation spanning immunology, oncology, rare diseases and blood disorders, vaccines, and consumer healthcare. Sanofi has a long legacy in diabetes (insulin glargine/Lantus was the world's best-selling insulin for over a decade), cardiovascular disease (alirocumab/Praluent for LDL reduction), and multiple sclerosis (teriflunomide/Aubagio, alemtuzumab/Lemtrada).
Sanofi's research transformation in recent years has concentrated investment heavily on immunology and inflammation — particularly the dupilumab program co-developed with Regeneron — and on rare blood disorders and oncology. In oncology, cemiplimab (Libtayo), a PD-1 inhibitor, is a key asset with multiple active indications. Sanofi acquired Translate Bio (mRNA technology) and Kadmon (itepekimab for COPD and pediatric asthma) and has early programs in mRNA therapeutics for cancer and infectious disease. The Rare Diseases unit — historically Genzyme — is a global leader in enzyme replacement therapy for lysosomal storage disorders.
Sanofi Pasteur, the company's vaccine division, is one of the world's largest vaccine producers, with approved vaccines for influenza, dengue, meningococcal disease, typhoid, rabies, and others, and active clinical trials in RSV, mRNA influenza, and pandemic preparedness. Sanofi conducts clinical research through partnerships with NIH, BARDA, CEPI, and academic institutions globally, and runs one of the most active Phase 3 trial programs in the rare disease space.